[
  {
    "ts": null,
    "headline": "Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment",
    "summary": "Merck is advancing the global development of sac-TMT through multiple ongoing Phase 3 trials.",
    "url": "https://finnhub.io/api/news?id=0715f62cc429526fdcc6bad8f85f820e1ced43e22d0837d0d5e611175f888e07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733256638,
      "headline": "Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment",
      "id": 131759419,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/c710e914e2dd00772dd3b1fd809d2f8a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is advancing the global development of sac-TMT through multiple ongoing Phase 3 trials.",
      "url": "https://finnhub.io/api/news?id=0715f62cc429526fdcc6bad8f85f820e1ced43e22d0837d0d5e611175f888e07"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)",
    "summary": "Merck &amp; Co., Inc. (NYSE:MRK) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ETCompany ParticipantsPeter Dannenbaum - SVP,...",
    "url": "https://finnhub.io/api/news?id=7a026e38c502b65bb8ea2275f38ef1e37b70594e0a004a6874343e6a46af6096",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733247668,
      "headline": "Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)",
      "id": 131759249,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck &amp; Co., Inc. (NYSE:MRK) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ETCompany ParticipantsPeter Dannenbaum - SVP,...",
      "url": "https://finnhub.io/api/news?id=7a026e38c502b65bb8ea2275f38ef1e37b70594e0a004a6874343e6a46af6096"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5a8ea5f59bd7f34c8a8202b863bb29b0e42d309bccf29a724d6b4471a3c5e884",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733243700,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 131775679,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5a8ea5f59bd7f34c8a8202b863bb29b0e42d309bccf29a724d6b4471a3c5e884"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations",
    "summary": "RAHWAY, N.J., December 03, 2024--FDA Grants Breakthrough Therapy Designation to sac-TMT for Certain Patients With Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations",
    "url": "https://finnhub.io/api/news?id=1a9d8afa678503d49af0ea5ec16f5313dd21786f7c26aea98b94f2463c14695b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733226300,
      "headline": "FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations",
      "id": 131753041,
      "image": "https://media.zenfs.com/en/business-wire.com/b7767977b52835f486b579cd415295e2",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 03, 2024--FDA Grants Breakthrough Therapy Designation to sac-TMT for Certain Patients With Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations",
      "url": "https://finnhub.io/api/news?id=1a9d8afa678503d49af0ea5ec16f5313dd21786f7c26aea98b94f2463c14695b"
    }
  },
  {
    "ts": null,
    "headline": "Merck: 'therapeutic breakthrough' for antibody-conjugate",
    "summary": "Merck announced on Tuesday that the FDA had granted breakthrough therapy status to its antibody-conjugate project for the treatment of a specific form of bronchial cancer.The pharmaceutical group...",
    "url": "https://finnhub.io/api/news?id=b67959f094704318118c714b6ec95840a7635b7e3bf3e7b3d6333a2717e3d13b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733215694,
      "headline": "Merck: 'therapeutic breakthrough' for antibody-conjugate",
      "id": 131752267,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced on Tuesday that the FDA had granted breakthrough therapy status to its antibody-conjugate project for the treatment of a specific form of bronchial cancer.The pharmaceutical group...",
      "url": "https://finnhub.io/api/news?id=b67959f094704318118c714b6ec95840a7635b7e3bf3e7b3d6333a2717e3d13b"
    }
  }
]